ABOUT CENCORA
Cencora combines core pharmaceutical distribution with innovative business solutions to help our partners across the healthcare spectrum get medications to the patients who need them. Biopharmaceutical companies benefit from the global scale and resources of a company ranked #10 on the Fortune 500, combined with local expertise provided by more than 51,000 team members worldwide. Learn more at www.cencora.com.
Whether you are developing and commercializing small molecules, biologics, or advanced therapies, Cencora can provide the deep scientific, regulatory, and technical expertise you need across the product life cycle. Our regulatory affairs, operations, and CMC services help improve the speed, quality, and consistency of manufacturing through submissions and beyond to reduce risk and optimize product launches.
VIDEOS AND WEBINARS
-
![GettyImages-2149321181 colleagues, meeting]( "Integrated Quality, Regulatory, And Safety Services")
Integrated Quality, Regulatory, And Safety ServicesA single-vendor model for quality, regulatory, and safety services provides consistent project management and cost-effective scalability. Hear how integrated solutions support market entry and growth.
-
![GettyImages-1204037710 meeting]( "Understanding PRCI And Its Requirements")
Understanding PRCI And Its RequirementsNavigating Health Canada's clinical information disclosure process takes real precision and preparation. Ensure your submission stays compliant, on schedule, and ready for review.
-
![Cencora - Orchestration]( "Connecting Manufacturers And Providers To The Services Needed For Full End-To-End Patient And Order Management")
Connecting Manufacturers And Providers To The Services Needed For Full End-To-End Patient And Order ManagementStreamline complex cell and gene therapy logistics with an integrated platform that connects manufacturers with vital services, providing full visibility and control for a more efficient and successful patient journey.
-
![Strategic Logistics]( "Crafting Scalable Solutions For Maximum Reach And Success")
Crafting Scalable Solutions For Maximum Reach And SuccessIs your supply chain ready for a blockbuster cell and gene therapy launch? Industry leaders discuss selecting partners, managing risk, and scaling operations for maximum reach and success.
-
![Maximizing Impact]( "Maximizing Impact: Strategies For Building Robust Patient Support Programs")
Maximizing Impact: Strategies For Building Robust Patient Support ProgramsPanelists explore the entire patient journey, from diagnosis to treatment, sharing strategies for creating practical, seamless support systems that ensure access to innovative cell and gene therapies.
-
![Navigating Special Regulatory Pathways For Advanced Therapy Development Success]( "Navigating Special Regulatory Pathways For Advanced Therapy Development Success")
Navigating Special Regulatory Pathways For Advanced Therapy Development SuccessDon't let regulatory hurdles slow you down. Learn from leading experts about special designations like RMAT and PRIME to accelerate your advanced therapy development and ensure success.
CONTACT INFORMATION
Cencora
1 W 1st Ave.
Conshohocken, PA 19428
UNITED STATES
FEATURED INSIGHTS
-
![GettyImages-1293773576-lab-team-collaboration-planning-research]( "When CGT Supply Chains Break Down: 5 Operational Gaps That Put Patient Outcomes At Risk")
Examine five of the most consequential gaps in CGT supply chain performance and learn what high-functioning teams do differently to protect patient outcomes before a failure occurs.
-
![GettyImages-1388281743 pharmacy]( "Addressing A Critical Drug Shortage")
A critical drug shortage demanded regulatory action, importation support, and patient program readiness. See how integrated QA, 3PL, and PSP capabilities delivered operational readiness in three months.
-
![GettyImages-1451133080 meeting, strategy]( "Foreign Action Notification To Health Canada")
Health Canada is tightening foreign action reporting expectations. MAHs need to understand what the updated draft guidance means for their compliance and monitoring processes now.
-
![GettyImages-2012460609 meeting, office, business]( "Specialist PV Support Transforms Safety For Orphan Medicinal Products")
Learn how a UK-based company developing two orphan-designated, centrally authorized therapies successfully navigated operational challenges after transitioning from a prior provider.
-
![GettyImages-2161842577-business-professional-laptop-office-table]( "Boosting Quality And Reducing Complexity With A Single-Provider PV Solution")
Discover how a German biopharmaceutical company successfully managed growing global pharmacovigilance complexity across more than 2,300 marketing authorizations and a broad partner network.
LEARN MORE ABOUT OUR SOLUTIONS
-
![GettyImages-891264822 planning, meeting]( "The Benefits Of Engaging In Pre-Approval Information Exchange (PIE)")
Explore the top 3 insights on the impact of pre-approval communication and learn why healthcare decision makers want more pre-approval resources and engagement from manufacturers.
WHITE PAPERS
-
![iStock-1200038380-stock-finance-chart-CFO]( "International Reference Pricing (IRP): Foundations, Shifts, And What To Do Next")
International Reference Pricing (IRP): Foundations, Shifts, And What To Do NextAs global pricing reforms evolve and policies gain traction, stakeholders must critically reassess the role of International Reference Pricing in balancing affordability, access, and incentives for innovation.
-
![GettyImages-1137143869 world map]( "Unlock The Potential Of Pharmacovigilance Outsourcing")
Unlock The Potential Of Pharmacovigilance OutsourcingOutsourcing pharmacovigilance can reduce overhead, strengthen compliance, and free teams to focus on innovation. Examine what a well-structured global PV model actually looks like in practice.
